Director/PDMR Shareholding

RNS Number : 2543D

Hikma Pharmaceuticals Plc

18 March 2011

 



Hikma Pharmaceuticals PLC - LTIP Awards

LONDON, 18 March 2011: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) announces that the Remuneration Committee has made the following nil-cost awards under the Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan (the "LTIP") to Persons Discharging Managerial Responsibility ("PDMR") of the Company.

Awards under the LTIP were made on 18 March 2011 at a price of £7.23p per ordinary share as follows:-

Name of Director/PDMR	Number of LTIP Shares
Bassam Kanaan	50,400
Michael Raya	45,200
Khalid Nabilsi	37,000
Majda Labadi	25,800

The shares subject to the LTIP awards will only be released to the participants in three years time, subject to their continued employment and the satisfaction of the comparative Total Shareholder Return ("TSR"), sales growth, earnings per share ("EPS") growth and return on invested capital ("ROIC") performance targets. Half of the award is subject to TSR against the Comparator Group and requires at least upper quartile performance to vest in full. The remaining half is split equally between the financial targets and requires sales growth of 13%, EPS growth of 20% and ROIC of 12% to vest in full. Each target is measured individually and is independent of the other targets.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC         

Henry Knowles                                                [phone]

Company Secretary

Susan Ringdal                                                 [phone]

Investor Relations Director

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics".  Hikma's operations are based principally in the Middle East and North Africa ("MENA") region, where it is a market leader and sells across 17 countries, the United States and Europe.  In 2010, the Group achieved revenues of $731 million (2009 $637 million) and profit attributable to shareholders was $99 million (2009 $78 million).  For news and other information, please visit www.hikma.com.

 

END

 

 

RDSBLGDXSGBBGBI